1. Acknowledgement to Referees

   Acknowledgement to Referees 22 November 2023 Pages: 1655 - 1660

2. Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)

   • Sebastian Sten
   • Tim Cardilin
   • Peter Gennemark

   Leading Article Open access 12 October 2023 Pages: 1661 - 1672

   

3. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone

   • Roland Heinig
   • Thomas Eissing

   Review Article Open access 24 October 2023 Pages: 1673 - 1693

   

4. High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints

   • Anouk M. E. Jansen
   • Rob ter Heine
   • Roger J. M. Brüggemann

   Commentary Open access 11 October 2023 Pages: 1695 - 1699

   

5. Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies

   • Anouk M. E. Jansen
   • Beatrijs Mertens
   • Roger J. M. Brüggemann

   Original Research Article Open access 11 October 2023 Pages: 1701 - 1711

   

6. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

   • Anne-Kristina Mercier
   • Mikael Sunnåker
   • Jan Oscarsson

   Original Research Article Open access 06 October 2023 Pages: 1713 - 1724

   

7. Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen

   • Angel Luis Salcedo-Mingoarranz
   • Susanna Edith Medellín-Garibay
   • Benito García-Díaz

   Original Research Article 10 October 2023 Pages: 1725 - 1738

   

8. Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

   • Yuan Li
   • Ying Zheng
   • Hongyan Guo

   Original Research Article 14 October 2023 Pages: 1739 - 1748

   

9. Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment

   • Leila S. Otten
   • Berber Piet
   • Michel M. van den Heuvel

   Original Research Article Open access 19 October 2023 Pages: 1749 - 1754

   

10. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

    • Hironobu Tsukada
    • Yu-Luan Chen
    • Gerald R. Galluppi

    Original Research Article Open access 26 October 2023 Pages: 1755 - 1763

    

11. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

    • Jessica Wojciechowski
    • Vivek S Purohit
    • Timothy Nicholas

    Original Research Article Open access 02 November 2023 Pages: 1765 - 1779